Inhibition of BRAF and MEK in BRAF-mutant melanoma
Mené sur 423 patients atteints d'un mélanome de stade IIIC ou IV présentant la mutation Val600Glu ou Val600Lys du gène BRAF, cet essai international de phase III évalue l'efficacité, du point de vue de la survie sans progression et de la survie globale, et la toxicité de l'ajout du dabrafénib au tramétinib en traitement de première ligne
Developments in the treatment of disseminated melanoma continue apace. In The Lancet, Georgina Long and colleagues present long-term follow-up data from a large, multicentre, phase 3 clinical trial of patients with BRAF Val600Glu/Lys mutant melanoma, treated with the BRAF inhibitor dabrafenib plus either a placebo or the MEK inhibitor trametinib. The combination of BRAF and MEK inhibition is designed to inhibit the MAPK pathway vertically, with the hope of preventing or delaying resistance arising from reactivation of MEK–ERK signalling that typically occurs after single-agent BRAF inhibition.
The Lancet , commentaire, 2014